Longitude (Cayman)’s Moderna MRNA Stock Holding History

Longitude (Cayman)’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$520K	Buy	+12,500	New	+$597K	0.11%	41

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Longitude (Cayman)'s MRNA Position: Q4 2021 in Review

Longitude (Cayman) sold out of Moderna (MRNA) in Q4 2021, closing a stake of 1,000 shares — an estimated $385K sold.

Longitude (Cayman) first reported a position in MRNA in Q2 2021 and held it in 2 quarters. The position peaked at $1.41M in Q2 2021. 1,109 funds tracked by Wall St. Rank hold MRNA as of Q4 2021.

Longitude (Cayman) reported no remaining Moderna position as of Q4 2021 after selling out during the quarter.
Longitude (Cayman) sold 1,000 Moderna shares in Q4 2021, an estimated $385K.
Longitude (Cayman) first reported a position in Moderna in Q2 2021 and held it in 2 quarters.
Longitude (Cayman)'s Moderna position peaked at $1.41M in Q2 2021.
1,109 funds tracked by Wall St. Rank held Moderna as of Q4 2021.

Based on Longitude (Cayman)'s 13F filing for Q4 2021, filed 3 Feb 2022.